From Wikipedia, the free encyclopedia
Ribonucleotide reductase inhibitors are a family of
anti-cancer drugs that interfere with the growth of
tumor cells by blocking the formation of
deoxyribonucleotides (building blocks of
DNA).
Examples include:
See also
References
-
^ Zahedi Avval F, Berndt C, Pramanik A, Holmgren A (January 2009). "Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd)". Biochem. Biophys. Res. Commun. 379 (3): 775–9.
doi:
10.1016/j.bbrc.2008.12.128.
PMID
19121624.
-
^ Mayhew CN, Phillips JD, Cibull ML, Elford HL, Gallicchio VS (September 2002).
"Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea". Antivir. Chem. Chemother. 13 (5): 305–14.
doi:
10.1177/095632020201300506.
PMID
12630679.
-
^ Tsimberidou AM, Alvarado Y, Giles FJ (August 2002). "Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies". Expert Rev Anticancer Ther. 2 (4): 437–48.
doi:
10.1586/14737140.2.4.437.
PMID
12647987.
S2CID
30047759.
-
^ Bernstein LR (1998).
"Mechanisms of therapeutic activity for gallium" (PDF). Pharmacol. Rev. 50 (4): 665–682.
PMID
9860806.
-
^ Bitonti, A. J.; Dumont, J. A.; Bush, T. L.; Cashman, E. A.; Cross-Doersen, D. E.; Wright, P. S.; Matthews, D. P.; McCarthy, J. R.; Kaplan, D. A. (15 March 1994).
"Regression of human breast tumor xenografts in response to (E)-2'-deoxy-2'-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase". Cancer Research. 54 (6): 1485–1490.
PMID
8137252.
-
^
"Tezacitabine monohydrate".
External links
This article incorporates
public domain material from
Dictionary of Cancer Terms.
U.S. National Cancer Institute.